header advert
Results 1 - 3 of 3
Results per page:
Applied filters
Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 93-B, Issue SUPP_III | Pages 351 - 351
1 Jul 2011
Varvarousis D Papadopoulos A Ploumis A Kanellakopoulou K Beris A Giamarellou H
Full Access

To compare usual practices against published guidelines of Perioperative Antimicrobial Prophylaxis (AP), which is an established method to reduce the risk of postoperative infection in TJR.

We prospectively evaluated AP in 616 patients, who underwent TJR of the hip and the knee in an ongoing cohort study. Teicoplanin was administered once perioperatively (10mg/kg iv) in one group A (n=278), while in the other group B (n=338) AP was administered according to the usual practice (various antibiotic combinations, including hemisynthetic penicillins/penicillinase inhibitors, cephalosporins, aminoglycosides and quinolones for 2–10 days). An evaluation form and personal examination were used for data collection and monitoring. Patients were followed up for 2 years minimum.

The two groups did not statistically differ (p> 0.05) regarding overall postoperative infections. Superficial soft tissue infection developed in 9/616 pts. 1/278 in group A (0.4%) vs 8/338 in group B (2.4%) (p< 0.05). Deep SSI was rarely seen, 4/616 pts (0.6%). 2/278 in group A (0.7%) vs 2/338 in group B (0.6%) (p=NS). Mean duration of AP was significant higher in group B [6(IQR: 5–8.25)], p< 0.001 Mann-Whitney test. Only in group B, MRSA-MRCNS postoperative infections did appear. The duration (days) of glycopeptide antibiotic usage, therapeutic (group B) or prophylactic (group A), was comparable in both groups (p> 0.05).

Glycopeptide antibiotic prophylaxis for TJR leads to less postoperative infections compared to other antibiotic prophylaxis, but similar duration of overall glycopeptide usage (prophylactic and therapeutic) in both groups.


Orthopaedic Proceedings
Vol. 93-B, Issue SUPP_III | Pages 336 - 336
1 Jul 2011
Varvarousis D Papadopoulos A Ploumis A Kanellakopoulou K Beris A Giamarellou H
Full Access

Background: Perioperative Antimicrobial Prophylaxis (AP) is an established method to reduce the risk of intraoperative infection in TJR. Usual practices are not always compatible with published guidelines leading to excess morbidity, antibiotic overuse and emergence of resistance.

Methods: We prospectively evaluated AP in 616 patients, who underwent TJR of the hip and the knee in an ongoing cohort study. Teicoplanin was administered once perioperatively (10mg/kg iv) in one group A (n=278), while in the other group B (n=338) AP was administered according to the usual practice (various antibiotic combinations, including hemisynthetic penicillins/penicillinase inhibitors, cephalosporins, aminoglycosides and quinolones for 2–10 days). An evaluation form and personal examination were used for data collection and monitoring. Patients were followed up for 2 years minimum.

Results: The two groups did not statistically differ (p> 0.05) regarding overall postoperative infections. Superficial soft tissue infection developed in 9/616 pts. 1/278 in group A (0.4%) vs 8/338 in group B(2.4%) (p< 0.05). Deep SSI was rarely seen, 4/616 pts (0.6%). 2/278 in group A (0.7%) vs 2/338 in group B (0.6%) (p=NS). Mean duration of AP was significant higher in group B [6(IQR:5–8.25)], p< 0.001 Mann-Whitney test. Only in group B, MRSA-MRCNS postoperative infections did appear. The duration (days) of glycopeptide antibiotic usage, prophylactic (group A) or therapeutic (group B), was comparable in both groups (p> 0.05).

Conclusions: Glycopeptide antibiotic prophylaxis for TJR leads to less postoperative infections compared to other antibiotic prophylaxis, but similar duration of overall glycopeptide usage (prophylactic or therapeutic) in both groups.


Orthopaedic Proceedings
Vol. 91-B, Issue SUPP_II | Pages 307 - 307
1 May 2009
Papadopoulos A Sakka V Giannitsioti E Athanasia S Kouvelas K Koratzanis E Kanellakopoulou K Giamarellou H
Full Access

The objective of the present study is to analyse the clinical, microbiological, and therapeutic features of patients with infective spondylodiscitis (ISD), who were followed up in our Outpatient Bone Infection Clinic.

We retrospectively studied the epidemiological and clinical characteristics of all patients diagnosed with ISD from January 1998 to December 2006. Data were extracted from an electronic data base registry and patients’ files.

Sixty patients either with spontaneous (n= 42, 70%) or postoperative (n= 18, 30%) ISD were evaluated. Population mean age was 56 years, 33 (55%) were male and 27 (45%) were female. The infection was localised in the lumbar (78%), thoracic (18%) or cervical (4%) spine. Predominate symptoms were pain (87%) and fever (50%). Fistula was observed exclusively in postoperative ISD (45%). In spontaneous ISD, the major causes were Brucella spp (33%), gram positive cocci (12%), gram negative bacteria (14%), Mycobacterium tuberculosis (7%), while in 33% of cases no pathogen was detected. In postoperative episodes of ISD the major causes were gram positive cocci (45%), gram negative bacteria (30%) and polymicrobial infection was documented in 22% of cases while in 25% of cases no pathogen was detected. Based on clinical, laboratory and imaging (especially MRI) data, treatment was individualised. Most patients (88%) received a combined antimicrobial treatment. Patients with spontaneous pyogenic/brucellosis or tuberculous/post-operative ISD received treatment for a median duration of 8/12/10 months and the response rate was 84%/81%/55.5%, respectively. Surgery was necessary in 40% of postoperative ISD cases for healing, while only one spontaneous case required a surgical intervention.

ISD is more frequently localised at the lumbar level. Long term combination antimicrobial treatment may be essential. Surgery may be required in iatrogenic cases in the presence of foreign bodies.